Results 171 to 180 of about 149,400 (379)

A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells [PDF]

, 2004
Mark Duxbury, Hiromichi Ito, Éric Benoît, Talat Waseem, Stanley W. Ashley, Edward E. Whang   +5 more
openalex   +1 more source

Adipocytes Promote Cisplatin Resistance through Secreting A1BG and Regulating NAMPT/PARP1 Axis‐Mediated DNA Repair in Osteosarcoma

Advanced Science, EarlyView.
The proposed working model for how adipocytes participate in cisplatin resistance in osteosarcoma. The adipocytes secret A1BG and stabilize NAMPT, leading to increased NAD⁺ levels and subsequent increased PARP1‐mediated DNA repair, resulting in cisplatin resistance in osteosarcoma finally.
Yonghui Liang, Zhaohui Li, Lina Tang, Zhen Pan, Xiang Fei, Chen Tan, Aina He, Qingcheng Yang, Dongdong Cheng   +8 more
wiley   +1 more source

Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells [PDF]

, 2004
S Hövelmann, Thomas Beckers, Mathias Schmidt   +2 more
openalex   +1 more source

NPR1 Promotes Lipid Droplet Lipolysis to Enhance Mitochondrial Oxidative Phosphorylation and Fuel Gastric Cancer Metastasis

Advanced Science, EarlyView.
NPR1 induces lipolysis of stored lipid droplet and enhances mitochondrial oxidative phosphorylation to fuel gastric cancer metastasis. Specifically, NPR1‐mediated activation of PKG directly phosphorylates and activates HSL at Ser855 and Ser951, thereby driving lipolytic processes.
Huafeng Fu, Jie Zhang, Hengxing Chen, Haobin Hou, Huanjie Chen, Rongman Xie, Yanlei Chen, Jian Zhang, Dehua Liu, Leping Yan, Rui L. Reis, Joaquim M. Oliveira, Yulong He, Li Zhong, Qinbo Cai, Dongjie Yang   +15 more
wiley   +1 more source

NGR‐Modified CAF‐Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma

Advanced Science
Osteosarcoma (OS) chemoresistance presents a significant clinical challenge. This study aims to investigate the potential of using tumor vascular‐targeting peptide NGR‐modified cancer‐associated fibroblasts (CAFs)‐derived exosomes (exos) to deliver ...
Jianxin Du, Xiangwei Meng, Minghao Yang, Guancheng Chen, Jigang Li, Zengjun Zhu, Xuanxuan Wu, Wei Hu, Maojin Tian, Tao Li, Shuai Ren, Peiqing Zhao   +11 more
doaj   +1 more source

Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus [PDF]

, 2004
Bin Gu, Laura España, Olga Méndez, A. Torregrosa, Àngels Sierra   +4 more
openalex   +1 more source

DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR‐JAK2‐STAT3 Pathway

Advanced Science, EarlyView.
This study identifies a novel mechanism of nasopharyngeal carcinoma (NPC) cisplatin chemoresistance that DDAH1 expression is associated with cisplatin resistance in NPC cells primarily through the enhancement of the phosphoinositide Janus kinase 2 (JAK2)‐signal transducer and activator of transcription 3 (STAT3) pathway.
Jin‐Hao Yang, Li Yuan, Qiu‐Yan Chen, Kai‐Qi Lan, Liang‐Ji Li, Yu‐Chen Li, Xiao‐Yun Li, Xue‐Song Sun, Lin‐Quan Tang, Sai‐Lan Liu, Hai‐Qiang Mai   +10 more
wiley   +1 more source

SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target

Advanced Science, EarlyView.
The role of splicing factor 3A subunit 3 (SF3A3) in driving endometrial cancer (EC) progression and potential therapeutic interventions. SF3A3, a core component of the U2 small nuclear ribonucleoprotein (U2 snRNP), is upregulated in endometrial cancer (EC) and promotes tumor growth and cisplatin resistance. RNA‐binding protein immunoprecipitation (RIP)
Wei Yu, Yi Gu, Hengrui Zhang, Wunan Huang, Lei Sun, Liangjian Ma, Xiaolei Liang, Lexin Liu, Guiping Chen, Weihua Wang, Zhongkai Cao, Xue Li, Xiangjun Chen, Lidan Hu   +13 more
wiley   +1 more source

New compositions for the treatment of chemoresistant and/or potentially chemoresistant leukaemias

, 2009
SOMMARIO DELL'INVENZIONE L'invenzione della presente descrizione si basa sulla scoperta che la chemioresistenza in numerose forme leucemiche è eliminata o fortemente ridotta da un trattamento con almeno un composto per terapie antitumorali in combinazione con almeno un bloccante del canale di potassio hERG1.
ARCANGELI, ANNAROSA, Becchetti A., PILLOZZI, SERENA, MASSELLI, MARIKA, DE LORENZO, EMANUELE   +4 more
openaire   +2 more sources

Characterization of RhoA-mediated Chemoresistance in Gastric Cancer Cells [PDF]

, 2005
Won Ki Kang, In‐Kyoung Lee, Chaehwa Park   +2 more
openalex   +1 more source